How to build population level evidence for events that haven't happened
Airfinity welcomes some of the leading experts across the life science space to a live industry roundtable, where they discussed pre-emptive health economics,...
Executive Abstract
Speakers include:
→ Sasha Siegel, PhD, VP of Disease Outcomes at Airfinity
→ Matt Linley, PhD, Senior Director, Analytics and Forecasting at Airfinity
→ Sir Peter Donnelly, CEO and Founder of Genomics Plc and Emeritus Professor of Statistical Science at the University of Oxford
→ Prof. Lotte Steuten, PhD, Deputy Chief Executive of the Office of Health Economics (OHE)
→ Jean-Bernard Gruenberger, Director for Value & Access, Novartis Global Health
Unlock Report Access
Complete this brief form for instant PDF access.
Related Executive Research
White Paper
How To Choose An Immunoassay Platform For Cell & Gene Therapy Bioanalysis
The key factors to automating assay development to get results quicker Given the recent approval of an adeno-associated viral (AAV) vector gene therapy for spi...
Guide
Chronic Obstructive Pulmonary Disease- Pipeline Analysis 2018
There are total 141 molecules in pipeline (Company Molecules 90, University & Institute Molecules 51) in different phases of development. There are total 141 m...
White Paper
Increasing Patient Engagement and Helping Clinical Trials Reach Full Potential with the Clinical Research as a Care Option Model
Only 3% of people with cancer participate in clinical trials. CRAACO seamlessly integrates clinical research with medical care, so more patients and physicians...